Indium In-111 Ibritumomab Tiuxetan

RADIATION2 trials

Conditions

Adult Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueNodal Marginal Zone LymphomaPost-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Grade 1 Follicular Lymphoma

Phase 1

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

CompletedNCT00438880

Mayo ClinicAdult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma +9

Start: 2004-10-31End: 2014-11-30Updated: 2016-02-04

Phase 2

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

TerminatedNCT01434472

Fred Hutchinson Cancer CenterPost-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma +4

Start: 2011-11-16End: 2020-05-06Updated: 2021-07-20

Indium In-111 Ibritumomab Tiuxetan

Sponsors

Conditions

Phase 1

Phase 2